{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ABSSSI&page=2", "query": { "condition": "ABSSSI", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ABSSSI&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T18:14:32.999Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01119105", "title": "Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Infections", "Infection" ], "interventions": [ { "name": "BC-3781", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nabriva Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2010-05", "completion_date": "2011-02-03", "has_results": true, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 9, "location_summary": "Chula Vista, California • La Mesa, California • Oceanside, California + 6 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01119105" }, { "nct_id": "NCT03372941", "title": "Hospital Avoidance Strategies for ABSSSI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Skin Infection" ], "interventions": [ { "name": "Dalbavancin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-03-04", "completion_date": "2021-10-14", "has_results": true, "last_update_posted_date": "2022-12-09", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03372941" }, { "nct_id": "NCT02961764", "title": "Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Bacterial Skin and Skin Structure Infections" ], "interventions": [ { "name": "Usual Care", "type": "DRUG" }, { "name": "Dalbavancin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2016-11-29", "completion_date": "2019-03-29", "has_results": true, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Sylmar, California • Hartford, Connecticut + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sylmar", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02961764" }, { "nct_id": "NCT01252719", "title": "Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wound Infection", "Abscess", "Systemic Inflammation", "Cellulitis" ], "interventions": [ { "name": "Single-Dose IV Oritavancin Diphosphate", "type": "DRUG" }, { "name": "IV Vancomycin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melinta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 968, "start_date": "2010-12", "completion_date": "2012-11-30", "has_results": true, "last_update_posted_date": "2022-08-01", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252719" }, { "nct_id": "NCT03176134", "title": "A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Bacterial Skin and Skin Structure Infections" ], "interventions": [ { "name": "Tedizolid phosphate", "type": "DRUG" }, { "name": "Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "11 Years", "sex": "ALL", "summary": "1 Day to 11 Years" }, "enrollment_count": 100, "start_date": "2019-01-20", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 8, "location_summary": "San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03176134" }, { "nct_id": "NCT03873987", "title": "Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Bacterial Skin and Skin Structure Infection" ], "interventions": [ { "name": "Current Formulation of Oritavancin", "type": "DRUG" }, { "name": "Kimyrsa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melinta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2019-07-16", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 4, "location_summary": "Chula Vista, California • La Mesa, California • Burr Ridge, Illinois + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Burr Ridge", "state": "Illinois" }, { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03873987" }, { "nct_id": "NCT02600611", "title": "Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Skin Structures and Soft Tissue Infections" ], "interventions": [ { "name": "iclaprim", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Motif Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2015-11-01", "completion_date": "2017-01-30", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 16, "location_summary": "Buena Park, California • La Mesa, California • Long Beach, California + 12 more", "locations": [ { "city": "Buena Park", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600611" }, { "nct_id": "NCT02814916", "title": "Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Methicillin-Resistant Staphylococcus Aureus", "Bacterial Infections", "Staphylococcal Skin Infections" ], "interventions": [ { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Oxacillin", "type": "DRUG" }, { "name": "Flucloxacillin", "type": "DRUG" }, { "name": "Cefadroxil", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 199, "start_date": "2017-03-30", "completion_date": "2024-01-01", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 15, "location_summary": "Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Palma", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02814916" }, { "nct_id": "NCT01421511", "title": "TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Skin and Subcutaneous Tissue Bacterial Infections" ], "interventions": [ { "name": "TR-701 FA", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 666, "start_date": "2011-09-15", "completion_date": "2013-01-10", "has_results": true, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 35, "location_summary": "Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421511" }, { "nct_id": "NCT02925416", "title": "Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Skin Diseases, Bacterial" ], "interventions": [ { "name": "Oritavancin", "type": "DRUG" }, { "name": "Placebo (D5W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2017-01-24", "completion_date": "2017-06-20", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-07-22T18:14:32.999Z", "location_count": 1, "location_summary": "Somers Point, New Jersey", "locations": [ { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02925416" } ] }